References: US Food and Drug Administration. FDA requires Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and Pfizer based on data that suggest there may be a link between the ...

Last summer, a group of scientists in Quebec analyzed the risk of Guillain-Barré syndrome in millions of people given the vaccine in Canada between 2009 and 2010 and reported 83 confirmed cases ...

Cite this: MHRA Advises on Rare Guillain-Barré Syndrome Risk After RSV Vaccination - Medscape - July 08, 2025. Comments Commenting is limited to medical professionals.